Many of our client providers – weight loss clinics, med spas, and full practice authority APRN providers – have been monitoring the FDA’s stance on tirzepatide throughout 2024. Compounding pharmacies may compound, and providers may prescribe, tirzepatide for as long as tirzepatide is on the FDA’s drug shortage list. On October 2, 2024, the FDA removed tirzepatide from its drug shortage list, causing concern and confusion among providers about how much longer and under what circumstances they could continue to prescribe tirzepatide legally.
Then, in late October, the FDA reversed course and allowed the compounding of tirzepatide to continue.
1818 is monitoring closely the FDA’s stance on compounding tirzepatide and semaglutide, along with the recent Novo Nordisk lawsuits against med spas and weight loss clinics regarding the Ozempic and Wegovy tradenames.
The evolving regulatory environment underscores the importance of staying informed and proactive. Providers must not only understand the current legal landscape but also anticipate potential changes that could impact their ability to prescribe compounded medications like tirzepatide. Failing to comply with FDA regulations can lead to serious consequences, including professional disciplinary action. Partnering with knowledgeable legal counsel ensures that you remain compliant while continuing to provide the best care for your patients.
If you are a prescriber and need compliance guidance and updates related to the FDA’s stance on compounding tirzepatide and other weight loss medications for weight loss and potential changes, please contact 1818 today. Our experienced attorneys can help you effectively navigate the weight loss clinic/ med spa process, protect your rights, and advocate for your best interests.
Call us at (312) 779-1818 or fill out our online contact form for further assistance and expert advice.
